Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies (Q38181994)

30 August 2017

title

Osteopontin is a promoter for hepatocellular carcinoma metastasis: a summary of 10 years of studies (English)

1 reference

30 August 2017

main subject

hepatocellular carcinoma

1 reference

Lunxiu Qin

1

1 reference

30 August 2017

publication date

25 January 2014

1 reference

30 August 2017

published in

Frontiers of medicine

1 reference

30 August 2017

volume

8

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

24-32

1 reference

Systemic endocrine instigation of indolent tumor growth requires osteopontin

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Role of osteopontin in cellular signaling and toxicant injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

P700: the primary electron donor of photosystem I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Elevated plasma osteopontin associated with gastric cancer development, invasion and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Expression and prognostic significance of osteopontin and caspase-3 in hepatocellular carcinoma patients after curative resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Postoperative serum osteopontin level is a novel monitor for treatment response and tumor recurrence after resection of hepatitis B-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Thrombin is a therapeutic target for metastatic osteopontin-positive hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Genomic aberrations in hepatocellular carcinoma related to osteopontin expression detected by array-CGH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Osteopontin promoter polymorphisms at locus -443 significantly affect the metastasis and prognosis of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Increased expression of osteopontin contributes to the progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Role of the metastasis-promoting protein osteopontin in the tumour microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Elevated plasma osteopontin levels in patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Role of osteopontin in cellular signaling and metastatic phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Mammalian initiator apoptotic caspases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Osteopontin is involved in the development of acquired chemo-resistance of cisplatin in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Thrombin-cleaved COOH(-) terminal osteopontin peptide binds with cyclophilin C to CD147 in murine breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Subcellular localization and analysis of apparent 180-kDa and 220-kDa proteins of the breast cancer susceptibility gene, BRCA1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Thrombin-cleaved osteopontin in synovial fluid of subjects with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Polymorphisms in the osteopontin promoter affect its transcriptional activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

The regulation and role of osteopontin in malignant transformation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Genetic polymorphims in promoter region of osteopontin gene may be a marker reflecting hepatitis activity in chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Cyclooxygenase‐2 gene promoter polymorphisms affect susceptibility to hepatitis C virus infection and disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Single-nucleotide polymorphism in the promoter region of the osteopontin gene at nucleotide -443 as a marker predicting the efficacy of pegylated interferon/ribavirin-therapy in Egyptians patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Structure of the osteopontin gene and its promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

The functional -443T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-Myb transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

Identification of osteopontin as a novel marker for early hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11684-014-0312-8

The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma

21 January 2018

1 reference

12 December 2020

The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model

1 reference

12 December 2020

Osteopontin contributes to hepatocyte growth factor-induced tumor growth and metastasis formation

1 reference

12 December 2020

Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin

1 reference

12 December 2020

Osteopontin expression in ductal adenocarcinomas and undifferentiated carcinomas of the pancreas

1 reference

12 December 2020

Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation.

1 reference

12 December 2020

Serial Plasma Osteopontin Levels Have Prognostic Value in Metastatic Breast Cancer

1 reference

12 December 2020

The impact of osteopontin promoter polymorphisms on the risk of calcium urolithiasis

1 reference

12 December 2020

The activation state of alphavbeta 3 regulates platelet and lymphocyte adhesion to intact and thrombin-cleaved osteopontin

1 reference

12 December 2020

The implication of osteopontin (OPN) expression and genetic polymorphisms of OPN promoter in oral carcinogenesis

1 reference

12 December 2020

SPP1 promoter polymorphisms: identification of the first modifier gene for pseudoxanthoma elasticum

1 reference

12 December 2020

Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival

1 reference

12 December 2020

Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9beta1 integrin

1 reference

12 December 2020

Two single-nucleotide polymorphisms in the 5' and 3' ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus

1 reference

12 December 2020

Tumor cells are the source of osteopontin and bone sialoprotein expression in human breast cancer.

1 reference

12 December 2020

Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis.

1 reference

12 December 2020

The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma

1 reference

12 December 2020

The metastasis gene osteopontin: a candidate target for cancer therapy

1 reference

12 December 2020

Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth.

1 reference

12 December 2020

10.1007/S11684-014-0312-8

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1027042003

0 references

1 reference